November 12, 2023Open Access

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Structured PICO

Does apixaban reduce stroke or systemic embolism in patients with subclinical atrial fibrillation?

Population

Patients with subclinical atrial fibrillation

Intervention

Apixaban

Comparator

Aspirin

Outcome

Stroke or systemic embolismhard clinical

In patients with subclinical atrial fibrillation, apixaban reduces the risk of stroke or systemic embolism compared to aspirin, but increases the risk of major bleeding.

Abstract

Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Jeff S. Healey

Renato D. Lópes

Christopher B. Granger

Journals

New England Journal of Medicine

Actions

Institutions

Duke University

Karolinska Institutet

Michigan State University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Structured PICO

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider